FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
19 letters match. Newest first.
-
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.
High risk -
DrugsPersōn & Covey, Inc.
FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.
High risk -
DrugsShiva Analyticals Private Limited
FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsApplied Therapeutics, Inc.
Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
DrugsGFA Production Xiamen Co., Ltd.
GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.
High risk -
DrugsGrupo Quimico SRL
FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.
High risk -
DrugsWestwood Laboratories LLC
FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.
High risk -
DrugsMedgel Private Limited
FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.
High risk -
DrugsNortec Quimica SA
FDA warned Brazil's Nortec Quimica, an API maker, over deleted lab data and weak quality unit review of batches exported to the U.S.
High risk -
DrugsColorful Products Corporation
FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.
High risk -
DrugsVi-Jon, LLC
FDA cited Vi-Jon for manufacturing-rule violations after finding microbial water contamination, leaks, weak investigations, and data-integrity failures in OTC drugs and cosmetics.
High risk -
DrugsUltra Seal Corporation
FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.
High risk -
DrugsAccu Bio-Chem Laboratories
FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.
Medium -
DrugsAdamson Analytical Laboratories, Inc.
FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.
High risk -
DrugsBBC Group Limited
FDA cites BBC Group Limited for data integrity, lab, equipment failures and unapproved, misbranded hand sanitizers.
High risk